These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15581204)

  • 1. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.
    Johnson JL; Nunn AJ; Fourie PB; Ormerod LP; Mugerwa RD; Mwinga A; Chintu C; Ngwira B; Onyebujoh P; Zumla A
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1348-54. PubMed ID: 15581204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.
    Mwinga A; Nunn A; Ngwira B; Chintu C; Warndorff D; Fine P; Darbyshire J; Zumla A;
    Lancet; 2002 Oct; 360(9339):1050-5. PubMed ID: 12383985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.
    Onyebujoh PC; Abdulmumini T; Robinson S; Rook GA; Stanford JL
    Respir Med; 1995 Mar; 89(3):199-207. PubMed ID: 7746913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis.
    Huang CY; Hsieh WY
    Hum Vaccin Immunother; 2017 Sep; 13(9):1960-1971. PubMed ID: 28604170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group.
    Lancet; 1999 Jul; 354(9173):116-9. PubMed ID: 10408487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.
    Dlugovitzky D; Fiorenza G; Farroni M; Bogue C; Stanford C; Stanford J
    Respir Med; 2006 Jun; 100(6):1079-87. PubMed ID: 16278080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.
    Mayo RE; Stanford JL
    Trans R Soc Trop Med Hyg; 2000; 94(5):563-8. PubMed ID: 11132390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration.
    Johnson JL; Kamya RM; Okwera A; Loughlin AM; Nyole S; Hom DL; Wallis RS; Hirsch CS; Wolski K; Foulds J; Mugerwa RD; Ellner JJ
    J Infect Dis; 2000 Apr; 181(4):1304-12. PubMed ID: 10753731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.
    Yang XY; Chen QF; Li YP; Wu SM
    PLoS One; 2011; 6(9):e23826. PubMed ID: 21909406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally administered Mycobacterium vaccae modulates expression of immunoregulatory molecules in BALB/c mice with pulmonary tuberculosis.
    Hernández-Pando R; Aguilar D; Orozco H; Cortez Y; Brunet LR; Rook GA
    Clin Vaccine Immunol; 2008 Nov; 15(11):1730-6. PubMed ID: 18827195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis?
    Stanford JL; Stanford CA; Grange JM; Lan NN; Etemadi A
    Respir Med; 2001 Jun; 95(6):444-7. PubMed ID: 11421500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.
    Stanford J; Stanford C; Grange J
    Front Biosci; 2004 May; 9():1701-19. PubMed ID: 14977580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis].
    Luo Y;
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jan; 24(1):43-7. PubMed ID: 11802939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
    Jenkins PA; Campbell IA; Banks J; Gelder CM; Prescott RJ; Smith AP
    Thorax; 2008 Jul; 63(7):627-34. PubMed ID: 18250184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB.
    Dlugovitzky D; Stanford C; Stanford J
    Immunotherapy; 2011 Apr; 3(4):557-68. PubMed ID: 21463195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential for immunotherapy with heat-killed Mycobacterium vaccae in respiratory medicine.
    Stanford J; Stanford C; Dlugovitzky D; Fiorenza G; Martinel-Lamas D; Selenscig D; Bogue C
    Immunotherapy; 2009 Nov; 1(6):933-47. PubMed ID: 20635912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis.
    Mayosi BM; Ntsekhe M; Bosch J; Pogue J; Gumedze F; Badri M; Jung H; Pandie S; Smieja M; Thabane L; Francis V; Thomas KM; Thomas B; Awotedu AA; Magula NP; Naidoo DP; Damasceno A; Banda AC; Mutyaba A; Brown B; Ntuli P; Mntla P; Ntyintyane L; Ramjee R; Manga P; Kirenga B; Mondo C; Russell JB; Tsitsi JM; Peters F; Essop MR; Barasa AF; Mijinyawa MS; Sani MU; Olunuga T; Ogah O; Adebiyi A; Aje A; Ansa V; Ojji D; Danbauchi S; Hakim J; Matenga J; Yusuf S
    Am Heart J; 2013 Feb; 165(2):109-15.e3. PubMed ID: 23351812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis.
    Dlugovitzky D; Notario R; Martinel-Lamas D; Fiorenza G; Farroni M; Bogue C; Stanford C; Stanford J
    Immunotherapy; 2010 Mar; 2(2):159-69. PubMed ID: 20635925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7).
    Butov DA; Efremenko YV; Prihoda ND; Zaitzeva SI; Yurchenko LV; Sokolenko NI; Butova TS; Stepanenko AL; Kutsyna GA; Jirathitikal V; Bourinbaiar AS
    Immunotherapy; 2013 Oct; 5(10):1047-54. PubMed ID: 24088075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis].
    Wang W; Jin G; Ye Y; Xia X; Wang A; Zhuang Y; Li G; Sun H; Wang Z; Lin M; Chen H; Li J; Dan Z; Zhang X
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 Feb; 22(2):108-10. PubMed ID: 11820954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.